Author for correspondence: Lasse Solskov, Institute of Pharmacology, Bartholin Building, University of Aarhus, University Park 1240, DK-8000 Aarhus C, Denmark (fax +45 8949 2150, e-mail [email protected]).

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Abstract: The UK Prospective Diabetes Study demonstrated that the hypoglycaemic drug metformin is associated with a reduction in cardiovascular events in a group of obese type 2 diabetes patients. The energy sensing enzyme AMP-activated protein kinase (AMPK) has been indicated to play an important protective role in the ischaemic heart and is activated by metformin. The aim of this study was to determine whether a single dose of metformin protects the myocardium against experimentally induced ischaemia 24 hr after the administration, and furthermore to determine whether a single dose of metformin results in an acute increase in myocardial AMPK activity. Wistar rats were given either a single oral dose of metformin (250 mg/kg body weight), or a single oral dose of saline. After 24 hr, the hearts were Langendorff-perfused and subjected to 45 min. of coronary artery occlusion. Infarct size was determined by staining with triphenyltetrazoliumchloride (TTC) and Evans Blue and expressed as a percentage of the risk zone (IS/AAR %). Isoform specific AMPK activity was measured 2 hr after administration of metformin or saline. Infarct size was significantly reduced in the metformin treated (I/R: 19.9 ± 3.9%versus 36.7 ± 3.6%, P < 0.01, n = 8–14) compared to the control group. A single oral dose of metformin resulted in an approximately ~2-fold increase in AMPK-α2 activity 2 hr after administration (P < 0.015, n = 10). In conclusion, a single dose of metformin results in an acute increase in myocardial AMPK activity measured 2 hr after administration and induces a significant reduction in myocardial infarct size 24 hr after metformin administration. Increased AMPK activity may be an important signal mediator involved in the mechanisms behind the cardioprotective effects afforded by metformin.

References

1 Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25–33.
10.7326/0003-4819-137-1-200207020-00009
CAS PubMed Web of Science® Google Scholar
2 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
10.1016/S0140-6736(98)07037-8
PubMed Web of Science® Google Scholar
3 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167–74.
10.1172/JCI13505
CAS PubMed Web of Science® Google Scholar
4 Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O et al . Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074–81.
10.2337/diabetes.51.7.2074
CAS PubMed Web of Science® Google Scholar
5 Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998; 67: 821–55.
10.1146/annurev.biochem.67.1.821
CAS PubMed Web of Science® Google Scholar
6 Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1–E10.
10.1152/ajpendo.1999.277.1.E1
CAS PubMed Web of Science® Google Scholar
7 Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15–25.
10.1016/j.cmet.2004.12.003
CAS PubMed Web of Science® Google Scholar
8 Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF et al . Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative {alpha}2 subunit of AMP-activated protein kinase. J Biol Chem 2003; 278: 28372–7.
10.1074/jbc.M303521200
CAS PubMed Web of Science® Google Scholar
9 Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al . AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495–503.
10.1172/JCI19297
PubMed Web of Science® Google Scholar
10 Yamashita N, Baxter GF, Yellon DM. Exercise directly enhances myocardial tolerance to ischaemia-reperfusion injury in the rat through a protein kinase C mediated mechanism. Heart 2001; 85: 331–6.
10.1136/heart.85.3.331
CAS PubMed Web of Science® Google Scholar
11 Penicaud L, Hitier Y, Ferre P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989; 262: 881–5.
10.1042/bj2620881
CAS PubMed Web of Science® Google Scholar
12 Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol 1994; 266: H714–9.
CAS PubMed Web of Science® Google Scholar
13 Kristiansen SB, Henning O, Nielsen-Kudsk JE, Botker HE, Nielsen TT. Effects of L-glutamate supplementation mimic effects of fasting in the ischemic heart. APMIS Suppl 2003; 117–21.
Google Scholar
14 Musi N, Fujii N, Hirshman MF, Ekberg I, Froberg S, Ljungqvist O et al . AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 2001; 50: 921–7.
10.2337/diabetes.50.5.921
CAS PubMed Web of Science® Google Scholar
15 Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, Holman GD et al . Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 2001; 50: 12–7.
10.2337/diabetes.50.1.12
CAS PubMed Web of Science® Google Scholar
16 Botker HE, Randsbaek F, Hansen SB, Thomassen A, Nielsen TT. Superiority of acid extractable glycogen for detection of metabolic changes during myocardial ischaemia. J Mol Cell Cardiol 1995; 27: 1325–32.
10.1016/S0022-2828(05)82395-8
CAS PubMed Web of Science® Google Scholar
17 Charlon V, Boucher F, Mouhieddine S, Deleiris J. Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary-artery ligation. Diabetes Metab 1988; 14: 591–5.
Web of Science® Google Scholar
18 Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hr after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88: 1264–72.
10.1161/01.CIR.88.3.1264
CAS PubMed Web of Science® Google Scholar
19 Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M et al . Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72: 1293–9.
10.1161/01.RES.72.6.1293
CAS PubMed Web of Science® Google Scholar
20 Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972–83.
10.1161/01.RES.87.11.972
CAS PubMed Web of Science® Google Scholar
21 Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51: 2420–5.
10.2337/diabetes.51.8.2420
CAS PubMed Web of Science® Google Scholar
22 Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226–32.
10.1074/jbc.M202489200
CAS PubMed Web of Science® Google Scholar
23 El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223–8.
10.1074/jbc.275.1.223
CAS PubMed Web of Science® Google Scholar
24 Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348(Pt 3): 607–14.
10.1042/bj3480607
CAS PubMed Web of Science® Google Scholar
25 Jensen LS, Kristiansen SB, Jessen N, Pold R, Buhl ES, Nielsen TT et al . Prior activation of the AMP-activated protein kinase by AICAR or exercise induces a cardioprotective effect against ischemic injury of the heart. Diabetologia 2003; 46: A50–1.
Web of Science® Google Scholar
26 Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999; 87: 1990–5.
10.1152/jappl.1999.87.5.1990
CAS PubMed Web of Science® Google Scholar
27 Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol 2003; 94: 1373–9.
10.1152/japplphysiol.00250.2002
CAS PubMed Web of Science® Google Scholar
28 Russell RR III, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999; 277: H643–9.
PubMed Web of Science® Google Scholar
29 Nishino Y, Miura T, Miki T, Sakamoto J, Nakamura Y, Ikeda Y et al . Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 2004; 61: 610–9.
10.1016/j.cardiores.2003.10.022
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume103, Issue1

July 2008

Pages 82-87

Metformin Induces Cardioprotection against Ischaemia/Reperfusion Injury in the Rat Heart 24 Hours after Administration

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Metformin Induces Cardioprotection against Ischaemia/Reperfusion Injury in the Rat Heart 24 Hours after Administration

Abstract

References

Citing Literature

References

Related

Information